LMK-235
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406579

CAS#: 1418033-25-6

Description: LMK-235 is a selective histone deacetylase (HDAC) 4 and HDAC5 inhibitor. LMK-235 demonstrates activity against chemoresistant cancer cell lines in an MTT assay for cytotoxicity using human ovarian cancer cell lines A2780 and cisplatin resistant A2780CisR (IC50 = 0.49 and 0.32 μ M respectively).


Price and Availability

Size
Price

5mg
USD 90
50mg
USD 450
500mg
USD 1650
5g
Ask price
Size
Price

10mg
USD 150
100mg
USD 650
1g
USD 2450
Size
Price

25mg
USD 250
200mg
USD 950
2g
USD 3650

LMK-235, purity > 98%, is in stock. The same day shipping out after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 406579
Name: LMK-235
CAS#: 1418033-25-6
Chemical Formula: C15H22N2O4
Exact Mass: 294.15796
Molecular Weight: 294.35
Elemental Analysis: C, 61.21; H, 7.53; N, 9.52; O, 21.74


Synonym: LMK235; LMK 235; LMK-235.

IUPAC/Chemical Name: N-((6-(hydroxyamino)-6-oxohexyl)oxy)-3,5-dimethylbenzamide

InChi Key: VRYZCEONIWEUAV-UHFFFAOYSA-N

InChi Code: InChI=1S/C15H22N2O4/c1-11-8-12(2)10-13(9-11)15(19)17-21-7-5-3-4-6-14(18)16-20/h8-10,20H,3-7H2,1-2H3,(H,16,18)(H,17,19)

SMILES Code: O=C(NOCCCCCC(NO)=O)C1=CC(C)=CC(C)=C1


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

  
 
 
 


References

1: Hansen FK, Sumanadasa SD, Stenzel K, Duffy S, Meister S, Marek L, Schmetter R, Kuna K, Hamacher A, Mordmüller B, Kassack MU, Winzeler EA, Avery VM, Andrews KT, Kurz T. Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages. Eur J Med Chem. 2014 Jul 23;82:204-13. doi: 10.1016/j.ejmech.2014.05.050. Epub 2014 May 22. PubMed PMID: 24904967.

2: Marek L, Hamacher A, Hansen FK, Kuna K, Gohlke H, Kassack MU, Kurz T. Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells. J Med Chem. 2013 Jan 24;56(2):427-36. doi: 10.1021/jm301254q. Epub 2013 Jan 8. PubMed PMID: 23252603.